Boniva, or ibandronate, is a prescription drug used for the treatment and prevention of osteoporosis in postmenopausal women. Osteoporosis is a disease characterized by a decline in bone density leading to an increased fragility of bones and resulting in a greater risk of fracture. Boniva prevents the breakdown and formation of bone, which indirectly leads to an increase in bone density. The medication is classified as a bisphosphonate, which is the preferred treatment for osteoporosis. However, Boniva may be contraindicated in some patients and a physician can determine if its use is recommended.
Inability to Sit or Stand
Boniva is administered once a month in the morning 60 minutes before any food or beverages. The patient must sit or stand for at least 60 minutes to prevent gastrointestinal irritation and stomach ulcers, explains the "Drug Information Handbook." The use of Boniva is contraindicated in patients who are bedridden or cannot sit or stand.
Hypocalcemia
Hypocalcemia occurs when calcium levels are below the normal range. The use of Boniva is contraindicated in patients who have hypocalcemia; the low levels of calcium must be corrected before initiating therapy. The patient may use over-the-counter calcium supplements according to the instructions of her physician. Patients on Boniva must be monitored regularly to ensure calcium levels are within the normal limits.
Esophagus Abnormality
Boniva may cause nausea, vomiting, abdominal pain and irritation on the esophagus. If a patient has an abnormality in the esophagus or has difficulty swallowing the medication, she should not use this drug.
Allergic Reactions
Allergic reactions may occur in about three percent of patients, according to the "Drug Information Handbook." Rash, itchiness and redness may occur in mild to moderate allergic reactions. A severe allergic reaction may include blisters, peeling, swelling of the lips or tongue, difficulty breathing and chest pain. If a patient experiences an allergic reaction, she should stop the medication immediately and receive medical help. The patient must never be prescribed the drug again.
References
- "Drug Information Handbook"; Charles F. Lacy, Lora L. Armstrong, et al.; 2007
- "Pharmacotherapy: A Pathophysiologic Approach"; Joseph T. Dipiro, Robert L. Talbert, et al.; 2008
Member Comments